Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

January 28, 2025

Conditions
Ulcerative Colitis
Interventions
DRUG

OSE-127

mAb antagonist to CD127 receptor (or IL-7Rα)

DRUG

Placebo

Normal saline

Trial Locations (55)

Unknown

Brest Regional Hospital, Brest

Grodno University Hospital, Grodno

Gomel Regional Clinical Hospital, Homyel

City Clinical Emergency Hospital, Minsk

Vitebsk Regional Clinical Hospital, Vitebsk

UZ Leuven - Department of Gastroenterology and Hepatology, Leuven

CHU Liège, Liège

Groupe Santé CHC - Clinique du Mont Légia, Liège

Medical Center Medconsult Pleven - OOD, Pleven

Medical Center Medconsult Pleven, Pleven

Acibadem City Clinic University Multiprofile Hospital for Active Treatment - EOOD, Clinic of Gastroenterology, Sofia

Medical Center Asklepion - Researches in humane medicine (EOOD), Sofia

Medical Center Asklepion, Sofia

Medical Center Hera EOOD, Sofia

Medical Center Hera, Sofia

UMHAT Tsaritsa Yoanna - ISUL - EAD, Sofia

Medical center VIP Clinic - OOD, Varna

Medical Center VIP Clinic, Varna

University Hospital Center Split, Split

EVEX Hospitals JSC, Kutaisi

West Regional Center of Modern Medical Technologies Ltd, Kutaisi

Institute of Clinical Cardiology, Tbilisi

Israel-Georgia Medical Research Clinic Helsicore Ltd, Tbilisi

JSC Clinic Jerarsi, Tbilisi

Multiprofile Clinic Consilium Medulla Ltd, Tbilisi

Clinexpert SMO, Budapest

II. Sz. Belgyogyaszati Klinika, Semmelweis Egyetem, Budapest

II. Sz Belgyogyasztai Intezet, Gasztroenterologia Debreceni Egyetem, Debrecen

Polana-D, Daugavpils

Liepāja Regional Hospital, Liepāja

Digestive Diseases Centre GASTRO, Riga

Pauls Stradins Clinical University Hospital, Riga

Centrum Opieki Zdrowotnej Orkan-med, Ksawerów

Centrum Medyczne Med-Gastr, Lodz

Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej, Lodz

Medicome Sp. z o.o., Oświęcim

Centrum Medyczne Medyk, Rzeszów

WIP Warsaw IBD Point Profesor Kierkus, Warsaw

Melita Medical, Wroclaw

Prof. S.V. Ochapovskiy Regional Clinical Hospital No.1, Krasnodar

Ryzhikh State Coloproctology Research Center, Moscow

LLC Novosibirskiy Gastrocenter, Novosibirsk

Medical Center Healthy Family LLC, Novosibirsk

State Budgetary Healthcare Institution of the Stavropol Region - Pyatigorsk Oncology Dispensary, Pyatigorsk

Saratov State Medical University, Saratov

Ekaterinburg City Clinical Hospital No. 14, Yekaterinburg

301 Fairfield Medical Suite, Cape Town

Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital - Dnipropetrovsk Regional Council, Dnipro

Prof. O.O. Salimov City Clinical Hospital #2 - Kharkiv City Council, Kharkiv

Kryvyi Rih City Clinical Hospital #2, Kryvyi Rih

Kyiv Regional Clinical Hospital - Kyiv Regional Council, Kyiv

Medical Center OK!Clinic+ of International Institute of Clinical Studies LLC, Kyiv

Ternopil University Hospital - Ternopil Regional Council, Ternopil

Andrii Novak Transcarpathian Regional Clinical Hospital, Uzhhorod

Municipal Institution City Clinical Hospital #6 - Therapeutic Department, Zaporizhzhya

Sponsors
All Listed Sponsors
lead

OSE Immunotherapeutics

INDUSTRY

NCT04882007 - Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter